nodes	percent_of_prediction	percent_of_DWPC	metapath
Linezolid—MAOB—Dopamine metabolism—TYR—melanoma	0.0367	0.252	CbGpPWpGaD
Linezolid—MAOA—Dopamine metabolism—TYR—melanoma	0.0231	0.158	CbGpPWpGaD
Linezolid—Rivaroxaban—ABCB1—melanoma	0.0112	1	CrCbGaD
Linezolid—MAOA—Melatonin metabolism and effects—MAP2—melanoma	0.00621	0.0425	CbGpPWpGaD
Linezolid—Phlebitis—Bleomycin—melanoma	0.00581	0.0069	CcSEcCtD
Linezolid—Candida infection—Carmustine—melanoma	0.00575	0.00682	CcSEcCtD
Linezolid—Neuropathy—Carmustine—melanoma	0.00565	0.00671	CcSEcCtD
Linezolid—Disorientation—Bleomycin—melanoma	0.0056	0.00664	CcSEcCtD
Linezolid—Sepsis—Dactinomycin—melanoma	0.00558	0.00663	CcSEcCtD
Linezolid—Candida infection—Temozolomide—melanoma	0.00556	0.00659	CcSEcCtD
Linezolid—Vaginal infection—Temozolomide—melanoma	0.00549	0.00652	CcSEcCtD
Linezolid—Neuropathy—Temozolomide—melanoma	0.00546	0.00648	CcSEcCtD
Linezolid—Injury—Bleomycin—melanoma	0.00545	0.00647	CcSEcCtD
Linezolid—Phlebitis—Dactinomycin—melanoma	0.00542	0.00643	CcSEcCtD
Linezolid—Erythema multiforme—Vemurafenib—melanoma	0.00541	0.00642	CcSEcCtD
Linezolid—Sepsis—Carmustine—melanoma	0.00523	0.0062	CcSEcCtD
Linezolid—Chills—Vemurafenib—melanoma	0.00513	0.00609	CcSEcCtD
Linezolid—Phlebitis—Carmustine—melanoma	0.00507	0.00602	CcSEcCtD
Linezolid—Thrombophlebitis—Carmustine—melanoma	0.00505	0.00599	CcSEcCtD
Linezolid—Erythema—Vemurafenib—melanoma	0.00498	0.00591	CcSEcCtD
Linezolid—Thrombophlebitis—Temozolomide—melanoma	0.00488	0.00579	CcSEcCtD
Linezolid—Dysgeusia—Vemurafenib—melanoma	0.00487	0.00578	CcSEcCtD
Linezolid—MAOA—Neurotransmitter Release Cycle—SLC6A11—melanoma	0.00487	0.0334	CbGpPWpGaD
Linezolid—MAOB—Alpha-synuclein signaling—PTK2B—melanoma	0.00484	0.0331	CbGpPWpGaD
Linezolid—Injury—Carmustine—melanoma	0.00476	0.00564	CcSEcCtD
Linezolid—MAOA—Serotonin Transporter Activity—ITGB3—melanoma	0.00457	0.0313	CbGpPWpGaD
Linezolid—Thirst—Temozolomide—melanoma	0.00444	0.00527	CcSEcCtD
Linezolid—Hyponatraemia—Carmustine—melanoma	0.00439	0.00521	CcSEcCtD
Linezolid—Gastrointestinal haemorrhage—Carmustine—melanoma	0.00437	0.00519	CcSEcCtD
Linezolid—Cough—Vemurafenib—melanoma	0.00434	0.00515	CcSEcCtD
Linezolid—Liver function test abnormal—Dactinomycin—melanoma	0.00431	0.00512	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Dactinomycin—melanoma	0.00421	0.00499	CcSEcCtD
Linezolid—Drug interaction—Docetaxel—melanoma	0.00417	0.00495	CcSEcCtD
Linezolid—MAOB—Alpha-synuclein signaling—SYK—melanoma	0.00411	0.0282	CbGpPWpGaD
Linezolid—Pancytopenia—Bleomycin—melanoma	0.00411	0.00488	CcSEcCtD
Linezolid—Anaphylactic shock—Vemurafenib—melanoma	0.00406	0.00482	CcSEcCtD
Linezolid—Liver function test abnormal—Carmustine—melanoma	0.00404	0.00479	CcSEcCtD
Linezolid—Hypokalaemia—Carmustine—melanoma	0.00398	0.00472	CcSEcCtD
Linezolid—Skin disorder—Vemurafenib—melanoma	0.00395	0.00468	CcSEcCtD
Linezolid—Pneumonia—Bleomycin—melanoma	0.00388	0.00461	CcSEcCtD
Linezolid—Hypokalaemia—Temozolomide—melanoma	0.00384	0.00456	CcSEcCtD
Linezolid—Pancytopenia—Dactinomycin—melanoma	0.00383	0.00455	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Temozolomide—melanoma	0.0038	0.00451	CcSEcCtD
Linezolid—MAOB—Biological oxidations—UGT2B10—melanoma	0.00379	0.026	CbGpPWpGaD
Linezolid—Neutropenia—Dactinomycin—melanoma	0.00377	0.00448	CcSEcCtD
Linezolid—Stomatitis—Bleomycin—melanoma	0.00376	0.00446	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Temozolomide—melanoma	0.00373	0.00442	CcSEcCtD
Linezolid—Candida infection—Docetaxel—melanoma	0.00369	0.00438	CcSEcCtD
Linezolid—Fluid retention—Docetaxel—melanoma	0.00367	0.00436	CcSEcCtD
Linezolid—Neuropathy—Docetaxel—melanoma	0.00363	0.00431	CcSEcCtD
Linezolid—Pneumonia—Dactinomycin—melanoma	0.00362	0.0043	CcSEcCtD
Linezolid—Pancytopenia—Carmustine—melanoma	0.00359	0.00426	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00357	0.00423	CcSEcCtD
Linezolid—Sweating increased—Temozolomide—melanoma	0.00356	0.00422	CcSEcCtD
Linezolid—Neutropenia—Carmustine—melanoma	0.00353	0.00419	CcSEcCtD
Linezolid—Decreased appetite—Vemurafenib—melanoma	0.00353	0.00419	CcSEcCtD
Linezolid—Stomatitis—Dactinomycin—melanoma	0.00351	0.00416	CcSEcCtD
Linezolid—Gastrointestinal disorder—Vemurafenib—melanoma	0.00351	0.00416	CcSEcCtD
Linezolid—Fatigue—Vemurafenib—melanoma	0.0035	0.00416	CcSEcCtD
Linezolid—Haemoglobin—Bleomycin—melanoma	0.00348	0.00413	CcSEcCtD
Linezolid—Constipation—Vemurafenib—melanoma	0.00347	0.00412	CcSEcCtD
Linezolid—Pancytopenia—Temozolomide—melanoma	0.00347	0.00411	CcSEcCtD
Linezolid—Haemorrhage—Bleomycin—melanoma	0.00346	0.00411	CcSEcCtD
Linezolid—Hypoaesthesia—Bleomycin—melanoma	0.00345	0.00409	CcSEcCtD
Linezolid—Neutropenia—Temozolomide—melanoma	0.00341	0.00405	CcSEcCtD
Linezolid—Hyperglycaemia—Carmustine—melanoma	0.00341	0.00404	CcSEcCtD
Linezolid—Upper respiratory tract infection—Temozolomide—melanoma	0.00339	0.00403	CcSEcCtD
Linezolid—Pneumonia—Carmustine—melanoma	0.00339	0.00402	CcSEcCtD
Linezolid—Sepsis—Docetaxel—melanoma	0.00336	0.00399	CcSEcCtD
Linezolid—Renal failure—Carmustine—melanoma	0.00331	0.00393	CcSEcCtD
Linezolid—Neuropathy peripheral—Carmustine—melanoma	0.0033	0.00392	CcSEcCtD
Linezolid—Hyperglycaemia—Temozolomide—melanoma	0.00329	0.00391	CcSEcCtD
Linezolid—Stomatitis—Carmustine—melanoma	0.00328	0.0039	CcSEcCtD
Linezolid—Pneumonia—Temozolomide—melanoma	0.00327	0.00389	CcSEcCtD
Linezolid—Phlebitis—Docetaxel—melanoma	0.00326	0.00387	CcSEcCtD
Linezolid—Thrombophlebitis—Docetaxel—melanoma	0.00325	0.00385	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00323	0.00383	CcSEcCtD
Linezolid—Body temperature increased—Vemurafenib—melanoma	0.00321	0.00381	CcSEcCtD
Linezolid—Pharyngitis—Dactinomycin—melanoma	0.00321	0.00381	CcSEcCtD
Linezolid—Neuropathy peripheral—Temozolomide—melanoma	0.00319	0.00379	CcSEcCtD
Linezolid—Stomatitis—Temozolomide—melanoma	0.00317	0.00377	CcSEcCtD
Linezolid—Chills—Bleomycin—melanoma	0.00311	0.00369	CcSEcCtD
Linezolid—Cardiac failure congestive—Docetaxel—melanoma	0.0031	0.00368	CcSEcCtD
Linezolid—MAOB—Tryptophan metabolism—CYP1B1—melanoma	0.00306	0.0209	CbGpPWpGaD
Linezolid—Erythema multiforme—Dactinomycin—melanoma	0.00306	0.00363	CcSEcCtD
Linezolid—Haemoglobin—Carmustine—melanoma	0.00304	0.00361	CcSEcCtD
Linezolid—Haemorrhage—Carmustine—melanoma	0.00302	0.00359	CcSEcCtD
Linezolid—Erythema—Bleomycin—melanoma	0.00302	0.00358	CcSEcCtD
Linezolid—Hypoaesthesia—Carmustine—melanoma	0.00301	0.00357	CcSEcCtD
Linezolid—Haemoglobin—Temozolomide—melanoma	0.00294	0.00349	CcSEcCtD
Linezolid—Haemorrhage—Temozolomide—melanoma	0.00292	0.00347	CcSEcCtD
Linezolid—Asthenia—Vemurafenib—melanoma	0.00291	0.00346	CcSEcCtD
Linezolid—Hypoaesthesia—Temozolomide—melanoma	0.00291	0.00345	CcSEcCtD
Linezolid—Pharyngitis—Temozolomide—melanoma	0.0029	0.00344	CcSEcCtD
Linezolid—Chills—Dactinomycin—melanoma	0.0029	0.00344	CcSEcCtD
Linezolid—Pruritus—Vemurafenib—melanoma	0.00287	0.00341	CcSEcCtD
Linezolid—Hyponatraemia—Docetaxel—melanoma	0.00282	0.00335	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—POU3F2—melanoma	0.00282	0.0193	CbGpPWpGaD
Linezolid—Erythema—Dactinomycin—melanoma	0.00281	0.00334	CcSEcCtD
Linezolid—Gastrointestinal haemorrhage—Docetaxel—melanoma	0.00281	0.00333	CcSEcCtD
Linezolid—Anaemia—Bleomycin—melanoma	0.00279	0.00331	CcSEcCtD
Linezolid—Diarrhoea—Vemurafenib—melanoma	0.00278	0.0033	CcSEcCtD
Linezolid—MAOA—Melatonin metabolism and effects—CYP1B1—melanoma	0.00277	0.019	CbGpPWpGaD
Linezolid—Erythema multiforme—Temozolomide—melanoma	0.00276	0.00328	CcSEcCtD
Linezolid—Tinnitus—Temozolomide—melanoma	0.00272	0.00323	CcSEcCtD
Linezolid—Leukopenia—Bleomycin—melanoma	0.0027	0.0032	CcSEcCtD
Linezolid—Dizziness—Vemurafenib—melanoma	0.00269	0.00319	CcSEcCtD
Linezolid—Erythema—Carmustine—melanoma	0.00263	0.00312	CcSEcCtD
Linezolid—Cough—Bleomycin—melanoma	0.00263	0.00312	CcSEcCtD
Linezolid—Chills—Temozolomide—melanoma	0.00262	0.00311	CcSEcCtD
Linezolid—Anaemia—Dactinomycin—melanoma	0.0026	0.00308	CcSEcCtD
Linezolid—Liver function test abnormal—Docetaxel—melanoma	0.00259	0.00308	CcSEcCtD
Linezolid—Vomiting—Vemurafenib—melanoma	0.00258	0.00307	CcSEcCtD
Linezolid—Rash—Vemurafenib—melanoma	0.00256	0.00304	CcSEcCtD
Linezolid—Dermatitis—Vemurafenib—melanoma	0.00256	0.00304	CcSEcCtD
Linezolid—Headache—Vemurafenib—melanoma	0.00255	0.00302	CcSEcCtD
Linezolid—Erythema—Temozolomide—melanoma	0.00254	0.00302	CcSEcCtD
Linezolid—Cramp muscle—Docetaxel—melanoma	0.00253	0.003	CcSEcCtD
Linezolid—Aspartate aminotransferase increased—Docetaxel—melanoma	0.00253	0.003	CcSEcCtD
Linezolid—Leukopenia—Dactinomycin—melanoma	0.00252	0.00299	CcSEcCtD
Linezolid—Dysgeusia—Temozolomide—melanoma	0.00249	0.00296	CcSEcCtD
Linezolid—Vision blurred—Carmustine—melanoma	0.00248	0.00294	CcSEcCtD
Linezolid—Alanine aminotransferase increased—Docetaxel—melanoma	0.00248	0.00294	CcSEcCtD
Linezolid—Anaphylactic shock—Bleomycin—melanoma	0.00246	0.00292	CcSEcCtD
Linezolid—Anaemia—Carmustine—melanoma	0.00243	0.00289	CcSEcCtD
Linezolid—Nausea—Vemurafenib—melanoma	0.00241	0.00286	CcSEcCtD
Linezolid—Thrombocytopenia—Bleomycin—melanoma	0.00241	0.00286	CcSEcCtD
Linezolid—Vision blurred—Temozolomide—melanoma	0.0024	0.00285	CcSEcCtD
Linezolid—MAOA—Biological oxidations—UGT2B10—melanoma	0.00238	0.0163	CbGpPWpGaD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.00238	0.0163	CbGpPWpGaD
Linezolid—Leukopenia—Carmustine—melanoma	0.00236	0.0028	CcSEcCtD
Linezolid—Anaemia—Temozolomide—melanoma	0.00235	0.00279	CcSEcCtD
Linezolid—Anorexia—Bleomycin—melanoma	0.00235	0.00278	CcSEcCtD
Linezolid—Angioedema—Temozolomide—melanoma	0.00232	0.00276	CcSEcCtD
Linezolid—Pancytopenia—Docetaxel—melanoma	0.00231	0.00274	CcSEcCtD
Linezolid—Vertigo—Temozolomide—melanoma	0.00229	0.00271	CcSEcCtD
Linezolid—Convulsion—Carmustine—melanoma	0.00228	0.00271	CcSEcCtD
Linezolid—Leukopenia—Temozolomide—melanoma	0.00228	0.0027	CcSEcCtD
Linezolid—Hypertension—Carmustine—melanoma	0.00227	0.0027	CcSEcCtD
Linezolid—Neutropenia—Docetaxel—melanoma	0.00227	0.00269	CcSEcCtD
Linezolid—Thrombocytopenia—Dactinomycin—melanoma	0.00225	0.00267	CcSEcCtD
Linezolid—MAOA—Melatonin metabolism and effects—EDN1—melanoma	0.00224	0.0154	CbGpPWpGaD
Linezolid—Cough—Temozolomide—melanoma	0.00222	0.00263	CcSEcCtD
Linezolid—Paraesthesia—Bleomycin—melanoma	0.00221	0.00262	CcSEcCtD
Linezolid—Convulsion—Temozolomide—melanoma	0.0022	0.00262	CcSEcCtD
Linezolid—Hypertension—Temozolomide—melanoma	0.0022	0.00261	CcSEcCtD
Linezolid—Dyspnoea—Bleomycin—melanoma	0.00219	0.0026	CcSEcCtD
Linezolid—Anorexia—Dactinomycin—melanoma	0.00219	0.0026	CcSEcCtD
Linezolid—Pneumonia—Docetaxel—melanoma	0.00218	0.00258	CcSEcCtD
Linezolid—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00215	0.00255	CcSEcCtD
Linezolid—Decreased appetite—Bleomycin—melanoma	0.00214	0.00254	CcSEcCtD
Linezolid—Renal failure—Docetaxel—melanoma	0.00213	0.00253	CcSEcCtD
Linezolid—Neuropathy peripheral—Docetaxel—melanoma	0.00212	0.00252	CcSEcCtD
Linezolid—Dry mouth—Temozolomide—melanoma	0.00212	0.00251	CcSEcCtD
Linezolid—Stomatitis—Docetaxel—melanoma	0.00211	0.0025	CcSEcCtD
Linezolid—Pain—Bleomycin—melanoma	0.0021	0.0025	CcSEcCtD
Linezolid—Thrombocytopenia—Carmustine—melanoma	0.0021	0.0025	CcSEcCtD
Linezolid—MAOA—Melatonin metabolism and effects—PRKCA—melanoma	0.0021	0.0144	CbGpPWpGaD
Linezolid—Anaphylactic shock—Temozolomide—melanoma	0.00208	0.00246	CcSEcCtD
Linezolid—Anorexia—Carmustine—melanoma	0.00205	0.00243	CcSEcCtD
Linezolid—Thrombocytopenia—Temozolomide—melanoma	0.00203	0.00241	CcSEcCtD
Linezolid—Skin disorder—Temozolomide—melanoma	0.00202	0.00239	CcSEcCtD
Linezolid—Hyperhidrosis—Temozolomide—melanoma	0.00201	0.00238	CcSEcCtD
Linezolid—MAOB—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.002	0.0137	CbGpPWpGaD
Linezolid—Decreased appetite—Dactinomycin—melanoma	0.002	0.00237	CcSEcCtD
Linezolid—Fatigue—Dactinomycin—melanoma	0.00198	0.00235	CcSEcCtD
Linezolid—Anorexia—Temozolomide—melanoma	0.00198	0.00235	CcSEcCtD
Linezolid—Pain—Dactinomycin—melanoma	0.00196	0.00233	CcSEcCtD
Linezolid—Urticaria—Bleomycin—melanoma	0.00196	0.00232	CcSEcCtD
Linezolid—Haemoglobin—Docetaxel—melanoma	0.00195	0.00232	CcSEcCtD
Linezolid—Body temperature increased—Bleomycin—melanoma	0.00195	0.00231	CcSEcCtD
Linezolid—Haemorrhage—Docetaxel—melanoma	0.00194	0.00231	CcSEcCtD
Linezolid—Insomnia—Carmustine—melanoma	0.00194	0.00231	CcSEcCtD
Linezolid—Hypoaesthesia—Docetaxel—melanoma	0.00193	0.00229	CcSEcCtD
Linezolid—Paraesthesia—Carmustine—melanoma	0.00193	0.00229	CcSEcCtD
Linezolid—Pharyngitis—Docetaxel—melanoma	0.00193	0.00229	CcSEcCtD
Linezolid—Dyspnoea—Carmustine—melanoma	0.00192	0.00227	CcSEcCtD
Linezolid—Somnolence—Carmustine—melanoma	0.00191	0.00227	CcSEcCtD
Linezolid—Insomnia—Temozolomide—melanoma	0.00188	0.00223	CcSEcCtD
Linezolid—Gastrointestinal pain—Dactinomycin—melanoma	0.00188	0.00223	CcSEcCtD
Linezolid—Decreased appetite—Carmustine—melanoma	0.00187	0.00222	CcSEcCtD
Linezolid—Paraesthesia—Temozolomide—melanoma	0.00186	0.00221	CcSEcCtD
Linezolid—Gastrointestinal disorder—Carmustine—melanoma	0.00185	0.0022	CcSEcCtD
Linezolid—Dyspnoea—Temozolomide—melanoma	0.00185	0.0022	CcSEcCtD
Linezolid—Somnolence—Temozolomide—melanoma	0.00185	0.00219	CcSEcCtD
Linezolid—Erythema multiforme—Docetaxel—melanoma	0.00184	0.00218	CcSEcCtD
Linezolid—Constipation—Carmustine—melanoma	0.00184	0.00218	CcSEcCtD
Linezolid—Pain—Carmustine—melanoma	0.00184	0.00218	CcSEcCtD
Linezolid—Dyspepsia—Temozolomide—melanoma	0.00183	0.00217	CcSEcCtD
Linezolid—Body temperature increased—Dactinomycin—melanoma	0.00181	0.00215	CcSEcCtD
Linezolid—Abdominal pain—Dactinomycin—melanoma	0.00181	0.00215	CcSEcCtD
Linezolid—Decreased appetite—Temozolomide—melanoma	0.0018	0.00214	CcSEcCtD
Linezolid—Gastrointestinal disorder—Temozolomide—melanoma	0.00179	0.00213	CcSEcCtD
Linezolid—Fatigue—Temozolomide—melanoma	0.00179	0.00212	CcSEcCtD
Linezolid—Constipation—Temozolomide—melanoma	0.00178	0.00211	CcSEcCtD
Linezolid—Pain—Temozolomide—melanoma	0.00178	0.00211	CcSEcCtD
Linezolid—Asthenia—Bleomycin—melanoma	0.00177	0.0021	CcSEcCtD
Linezolid—Gastrointestinal pain—Carmustine—melanoma	0.00176	0.00208	CcSEcCtD
Linezolid—Chills—Docetaxel—melanoma	0.00174	0.00207	CcSEcCtD
Linezolid—Pruritus—Bleomycin—melanoma	0.00174	0.00207	CcSEcCtD
Linezolid—Body temperature increased—Carmustine—melanoma	0.0017	0.00202	CcSEcCtD
Linezolid—Abdominal pain—Carmustine—melanoma	0.0017	0.00202	CcSEcCtD
Linezolid—Gastrointestinal pain—Temozolomide—melanoma	0.0017	0.00201	CcSEcCtD
Linezolid—Erythema—Docetaxel—melanoma	0.00169	0.00201	CcSEcCtD
Linezolid—Dysgeusia—Docetaxel—melanoma	0.00166	0.00197	CcSEcCtD
Linezolid—Urticaria—Temozolomide—melanoma	0.00165	0.00196	CcSEcCtD
Linezolid—Asthenia—Dactinomycin—melanoma	0.00165	0.00195	CcSEcCtD
Linezolid—Body temperature increased—Temozolomide—melanoma	0.00164	0.00195	CcSEcCtD
Linezolid—Abdominal pain—Temozolomide—melanoma	0.00164	0.00195	CcSEcCtD
Linezolid—Muscle spasms—Docetaxel—melanoma	0.00163	0.00193	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—MAP2—melanoma	0.00162	0.0111	CbGpPWpGaD
Linezolid—Diarrhoea—Dactinomycin—melanoma	0.00157	0.00186	CcSEcCtD
Linezolid—Vomiting—Bleomycin—melanoma	0.00156	0.00186	CcSEcCtD
Linezolid—Anaemia—Docetaxel—melanoma	0.00156	0.00186	CcSEcCtD
Linezolid—Rash—Bleomycin—melanoma	0.00155	0.00184	CcSEcCtD
Linezolid—Dermatitis—Bleomycin—melanoma	0.00155	0.00184	CcSEcCtD
Linezolid—Asthenia—Carmustine—melanoma	0.00154	0.00183	CcSEcCtD
Linezolid—Leukopenia—Docetaxel—melanoma	0.00151	0.0018	CcSEcCtD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP17A1—melanoma	0.00149	0.0102	CbGpPWpGaD
Linezolid—Asthenia—Temozolomide—melanoma	0.00149	0.00177	CcSEcCtD
Linezolid—Cough—Docetaxel—melanoma	0.00148	0.00175	CcSEcCtD
Linezolid—Diarrhoea—Carmustine—melanoma	0.00147	0.00174	CcSEcCtD
Linezolid—Pruritus—Temozolomide—melanoma	0.00147	0.00174	CcSEcCtD
Linezolid—Convulsion—Docetaxel—melanoma	0.00147	0.00174	CcSEcCtD
Linezolid—Nausea—Bleomycin—melanoma	0.00146	0.00173	CcSEcCtD
Linezolid—Hypertension—Docetaxel—melanoma	0.00146	0.00173	CcSEcCtD
Linezolid—Vomiting—Dactinomycin—melanoma	0.00146	0.00173	CcSEcCtD
Linezolid—Rash—Dactinomycin—melanoma	0.00145	0.00172	CcSEcCtD
Linezolid—MAOB—Tryptophan metabolism—MDM2—melanoma	0.00143	0.00979	CbGpPWpGaD
Linezolid—Dizziness—Carmustine—melanoma	0.00142	0.00169	CcSEcCtD
Linezolid—Diarrhoea—Temozolomide—melanoma	0.00142	0.00169	CcSEcCtD
Linezolid—Dry mouth—Docetaxel—melanoma	0.00141	0.00167	CcSEcCtD
Linezolid—MAOA—Transmission across Chemical Synapses—SLC6A11—melanoma	0.0014	0.00957	CbGpPWpGaD
Linezolid—Anaphylactic shock—Docetaxel—melanoma	0.00138	0.00164	CcSEcCtD
Linezolid—MAOA—SIDS Susceptibility Pathways—TP73—melanoma	0.00137	0.00941	CbGpPWpGaD
Linezolid—Dizziness—Temozolomide—melanoma	0.00137	0.00163	CcSEcCtD
Linezolid—Vomiting—Carmustine—melanoma	0.00137	0.00162	CcSEcCtD
Linezolid—Nausea—Dactinomycin—melanoma	0.00136	0.00162	CcSEcCtD
Linezolid—Rash—Carmustine—melanoma	0.00135	0.00161	CcSEcCtD
Linezolid—Dermatitis—Carmustine—melanoma	0.00135	0.00161	CcSEcCtD
Linezolid—Thrombocytopenia—Docetaxel—melanoma	0.00135	0.0016	CcSEcCtD
Linezolid—Headache—Carmustine—melanoma	0.00135	0.0016	CcSEcCtD
Linezolid—Skin disorder—Docetaxel—melanoma	0.00134	0.00159	CcSEcCtD
Linezolid—Vomiting—Temozolomide—melanoma	0.00132	0.00157	CcSEcCtD
Linezolid—Anorexia—Docetaxel—melanoma	0.00132	0.00156	CcSEcCtD
Linezolid—Rash—Temozolomide—melanoma	0.00131	0.00155	CcSEcCtD
Linezolid—Dermatitis—Temozolomide—melanoma	0.00131	0.00155	CcSEcCtD
Linezolid—Headache—Temozolomide—melanoma	0.0013	0.00154	CcSEcCtD
Linezolid—Nausea—Carmustine—melanoma	0.00128	0.00151	CcSEcCtD
Linezolid—MAOB—Biological oxidations—CYP17A1—melanoma	0.00126	0.00866	CbGpPWpGaD
Linezolid—MAOA—Phase 1 - Functionalization of compounds—CYP1B1—melanoma	0.00126	0.00861	CbGpPWpGaD
Linezolid—Insomnia—Docetaxel—melanoma	0.00125	0.00148	CcSEcCtD
Linezolid—Paraesthesia—Docetaxel—melanoma	0.00124	0.00147	CcSEcCtD
Linezolid—Nausea—Temozolomide—melanoma	0.00123	0.00146	CcSEcCtD
Linezolid—Dyspnoea—Docetaxel—melanoma	0.00123	0.00146	CcSEcCtD
Linezolid—Somnolence—Docetaxel—melanoma	0.00123	0.00146	CcSEcCtD
Linezolid—Dyspepsia—Docetaxel—melanoma	0.00122	0.00144	CcSEcCtD
Linezolid—Decreased appetite—Docetaxel—melanoma	0.0012	0.00142	CcSEcCtD
Linezolid—Gastrointestinal disorder—Docetaxel—melanoma	0.00119	0.00141	CcSEcCtD
Linezolid—Fatigue—Docetaxel—melanoma	0.00119	0.00141	CcSEcCtD
Linezolid—Constipation—Docetaxel—melanoma	0.00118	0.0014	CcSEcCtD
Linezolid—Pain—Docetaxel—melanoma	0.00118	0.0014	CcSEcCtD
Linezolid—Gastrointestinal pain—Docetaxel—melanoma	0.00113	0.00134	CcSEcCtD
Linezolid—Body temperature increased—Docetaxel—melanoma	0.00109	0.0013	CcSEcCtD
Linezolid—Abdominal pain—Docetaxel—melanoma	0.00109	0.0013	CcSEcCtD
Linezolid—MAOA—Melatonin metabolism and effects—NFKB1—melanoma	0.00109	0.00743	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—SLC6A11—melanoma	0.00107	0.00733	CbGpPWpGaD
Linezolid—MAOB—Biological oxidations—CYP1B1—melanoma	0.00106	0.00729	CbGpPWpGaD
Linezolid—MAOA—Oxidative Stress—NFKB1—melanoma	0.00106	0.00723	CbGpPWpGaD
Linezolid—Asthenia—Docetaxel—melanoma	0.000991	0.00118	CcSEcCtD
Linezolid—Pruritus—Docetaxel—melanoma	0.000977	0.00116	CcSEcCtD
Linezolid—Diarrhoea—Docetaxel—melanoma	0.000945	0.00112	CcSEcCtD
Linezolid—Dizziness—Docetaxel—melanoma	0.000913	0.00108	CcSEcCtD
Linezolid—Vomiting—Docetaxel—melanoma	0.000878	0.00104	CcSEcCtD
Linezolid—Rash—Docetaxel—melanoma	0.000871	0.00103	CcSEcCtD
Linezolid—Dermatitis—Docetaxel—melanoma	0.00087	0.00103	CcSEcCtD
Linezolid—Headache—Docetaxel—melanoma	0.000865	0.00103	CcSEcCtD
Linezolid—MAOA—Transmission across Chemical Synapses—GRIN2A—melanoma	0.000854	0.00585	CbGpPWpGaD
Linezolid—Nausea—Docetaxel—melanoma	0.00082	0.000973	CcSEcCtD
Linezolid—MAOA—Biological oxidations—CYP17A1—melanoma	0.000794	0.00543	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ACER3—melanoma	0.00071	0.00486	CbGpPWpGaD
Linezolid—MAOA—Biological oxidations—CYP1B1—melanoma	0.000668	0.00457	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—GRIN2A—melanoma	0.000654	0.00448	CbGpPWpGaD
Linezolid—MAOB—Metabolism—UGT2B10—melanoma	0.000649	0.00444	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HS3ST5—melanoma	0.000603	0.00413	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL10—melanoma	0.000577	0.00395	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—HIF1A—melanoma	0.000487	0.00333	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PLCB4—melanoma	0.000457	0.00313	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—PRKCA—melanoma	0.000449	0.00307	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ACER3—melanoma	0.000445	0.00305	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIP4K2A—melanoma	0.00043	0.00294	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC6A11—melanoma	0.00043	0.00294	CbGpPWpGaD
Linezolid—MAOB—Metabolism—MTAP—melanoma	0.000418	0.00286	CbGpPWpGaD
Linezolid—MAOA—Metabolism—UGT2B10—melanoma	0.000407	0.00279	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HS3ST5—melanoma	0.000379	0.00259	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PHGDH—melanoma	0.000373	0.00255	CbGpPWpGaD
Linezolid—MAOB—Metabolism—LUM—melanoma	0.000373	0.00255	CbGpPWpGaD
Linezolid—MAOB—Metabolism—HPSE—melanoma	0.000366	0.0025	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CUBN—melanoma	0.000359	0.00246	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SDHD—melanoma	0.000347	0.00237	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CSPG4—melanoma	0.000347	0.00237	CbGpPWpGaD
Linezolid—MAOB—Metabolism—BSG—melanoma	0.000347	0.00237	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—PRKCA—melanoma	0.000344	0.00235	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GPAM—melanoma	0.000336	0.0023	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—BRAF—melanoma	0.00033	0.00226	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CXCL8—melanoma	0.000316	0.00216	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CASP3—melanoma	0.000302	0.00207	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—CTNNB1—melanoma	0.000291	0.00199	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PLCB4—melanoma	0.000287	0.00196	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PLA2G6—melanoma	0.000285	0.00195	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—NFKB1—melanoma	0.000282	0.00193	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—MDM2—melanoma	0.000277	0.0019	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIP4K2A—melanoma	0.00027	0.00185	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC6A11—melanoma	0.00027	0.00185	CbGpPWpGaD
Linezolid—MAOA—Metabolism—MTAP—melanoma	0.000262	0.0018	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—VEGFA—melanoma	0.000256	0.00176	CbGpPWpGaD
Linezolid—MAOB—Metabolism—VCAN—melanoma	0.000256	0.00176	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—BRAF—melanoma	0.000253	0.00173	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PHGDH—melanoma	0.000234	0.0016	CbGpPWpGaD
Linezolid—MAOA—Metabolism—LUM—melanoma	0.000234	0.0016	CbGpPWpGaD
Linezolid—MAOA—Metabolism—HPSE—melanoma	0.000229	0.00157	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CUBN—melanoma	0.000225	0.00154	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—TNF—melanoma	0.00022	0.0015	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SDHD—melanoma	0.000217	0.00149	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CSPG4—melanoma	0.000217	0.00149	CbGpPWpGaD
Linezolid—MAOA—Metabolism—BSG—melanoma	0.000217	0.00149	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP17A1—melanoma	0.000216	0.00148	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—MDM2—melanoma	0.000212	0.00145	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GPAM—melanoma	0.000211	0.00144	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GNA11—melanoma	0.000204	0.0014	CbGpPWpGaD
Linezolid—MAOB—Metabolism—FASN—melanoma	0.0002	0.00137	CbGpPWpGaD
Linezolid—MAOB—Metabolism—SLC5A5—melanoma	0.000197	0.00135	CbGpPWpGaD
Linezolid—MAOB—Metabolism—GNAQ—melanoma	0.00019	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CD44—melanoma	0.00019	0.0013	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—MAPK1—melanoma	0.000189	0.0013	CbGpPWpGaD
Linezolid—MAOB—Metabolism—CYP1B1—melanoma	0.000182	0.00125	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PLA2G6—melanoma	0.000179	0.00123	CbGpPWpGaD
Linezolid—MAOA—SIDS Susceptibility Pathways—IL6—melanoma	0.000177	0.00121	CbGpPWpGaD
Linezolid—MAOA—Metabolism—VCAN—melanoma	0.000161	0.0011	CbGpPWpGaD
Linezolid—MAOA—Transmission across Chemical Synapses—HRAS—melanoma	0.000152	0.00104	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ABCB1—melanoma	0.00015	0.00103	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—MAPK1—melanoma	0.000145	0.000992	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PRKCA—melanoma	0.000138	0.000945	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ERCC2—melanoma	0.000137	0.000937	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP17A1—melanoma	0.000136	0.000929	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GNA11—melanoma	0.000128	0.000877	CbGpPWpGaD
Linezolid—MAOA—Metabolism—FASN—melanoma	0.000125	0.000859	CbGpPWpGaD
Linezolid—MAOA—Metabolism—SLC5A5—melanoma	0.000123	0.000845	CbGpPWpGaD
Linezolid—MAOA—Metabolism—GNAQ—melanoma	0.000119	0.000816	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CD44—melanoma	0.000119	0.000816	CbGpPWpGaD
Linezolid—MAOA—Neuronal System—HRAS—melanoma	0.000116	0.000797	CbGpPWpGaD
Linezolid—MAOA—Metabolism—CYP1B1—melanoma	0.000114	0.000782	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CG—melanoma	0.000108	0.00074	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PPARG—melanoma	0.000104	0.000714	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CD—melanoma	9.5e-05	0.00065	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ABCB1—melanoma	9.41e-05	0.000644	CbGpPWpGaD
Linezolid—MAOB—Metabolism—ALB—melanoma	9.38e-05	0.000642	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PRKCA—melanoma	8.66e-05	0.000593	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ERCC2—melanoma	8.59e-05	0.000588	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CB—melanoma	8.28e-05	0.000567	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTGS2—melanoma	8.2e-05	0.000562	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PTEN—melanoma	7.15e-05	0.00049	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CG—melanoma	6.78e-05	0.000464	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PPARG—melanoma	6.54e-05	0.000448	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CD—melanoma	5.96e-05	0.000408	CbGpPWpGaD
Linezolid—MAOA—Metabolism—ALB—melanoma	5.88e-05	0.000403	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CB—melanoma	5.2e-05	0.000356	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTGS2—melanoma	5.15e-05	0.000352	CbGpPWpGaD
Linezolid—MAOB—Metabolism—PIK3CA—melanoma	5.05e-05	0.000346	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PTEN—melanoma	4.49e-05	0.000307	CbGpPWpGaD
Linezolid—MAOB—Metabolism—AKT1—melanoma	4.12e-05	0.000282	CbGpPWpGaD
Linezolid—MAOA—Metabolism—PIK3CA—melanoma	3.17e-05	0.000217	CbGpPWpGaD
Linezolid—MAOA—Metabolism—AKT1—melanoma	2.59e-05	0.000177	CbGpPWpGaD
